SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 5.82 |
| Enterprise Value ($M) | 4.92 |
| Book Value ($M) | -1.21 |
| Book Value / Share | -0.27 |
| Price / Book | -4.80 |
| NCAV ($M) | -1.47 |
| NCAV / Share | -0.33 |
| Price / NCAV | -3.97 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -7.52 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.49 |
| Current Ratio | 0.49 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1.42 |
| Assets | 1.67 |
| Liabilities | 2.88 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -9.94 |
| Net Income | -9.95 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -8.27 |
| Cash from Investing | -0.15 |
| Cash from Financing | 3.65 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Ault Milton C Iii | 40.30 | 62.95 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 17,172 | 85,741 | 20.03 | |
| 47,875 | 127,522 | 37.54 | |
| 53,928 | 113,291 | 47.60 | |
| 74,610 | 201,354 | 37.05 | |
| 39,405 | 101,663 | 38.76 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALRN – Aileron Therapeutics, Inc. | ALTS – JanOne Inc. |
| ALVR – AlloVir, Inc. | ANEB – Anebulo Pharmaceuticals, Inc. |
| ANIX – Anixa Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io